Skip to main content
Consumer familiarity, perspectives and expected value of personalized medicine with a focus on applications in oncology
Published Web Location
http://www.futuremedicine.com/doi/abs/10.2217/pme.14.74No data is associated with this publication.
Abstract
Aims
Knowledge of consumer perspectives of personalized medicine (PM) is limited. Our study assessed consumer perspectives of PM, with a focus on oncology care, to inform industry, clinician and payer stakeholders' programs and policy.Materials & methods
A nationally representative survey of 602 US consumers' ≥30 years old explored familiarity, perspectives and expected value of PM.Results
Most (73%) respondents have not heard of 'personalized medicine,' though after understanding the term most (95%) expect PM to have a positive beneft. Consumer's willingness to pay is associated with products' impact on survival, rather than predicting disease risk. If testing indicates consumers are not candidates for oncology therapies, most (84%) would seek a second opinion or want therapy anyway.Conclusions
Understanding heterogeneity in consumer perspectives of PM can inform program and policy development.Many UC-authored scholarly publications are freely available on this site because of the UC's open access policies. Let us know how this access is important for you.